Abstract
PURPOSE: Despite extensive efforts and campaigns, infections continue to plague intensive care units. Ventilator associated pneumonia (VAP) is associated with relatively high mortality and morbidity rates and significantly increases length of stay in the ICU. Furthermore VAP is now considered a non-reimbursable complication with an estimated cost per patient range of $11, 897-$150,841. The purpose of this study was to explore our cardiac surgery patient population to discern which clinical variables may be modifiable to reduce the number of patients who develop VAP despite rigid implementation of the VAP prevention bundle.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
